OverviewSuggest Edit

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
The Company's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Alferon LDO. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.

TypePublic
Founded1990
HQPhiladelphia, US
Websitehemispherx.net
Employee Ratings2.1

Latest Updates

Employees (est.) (Feb 2019)25(-21%)
Revenue (FY, 2018)$367 K(-16%)
Share Price (May 2019)$0.1 (+3%)

Key People/Management at Hemispherx BioPharma

David R. Strayer

David R. Strayer

Chief Scientific & Medical Officer
Peter W. Rodino

Peter W. Rodino

Executive Director for Governmental Relations, General Counsel and Secretary
Wayne Springate

Wayne Springate

Senior Vice President of Operations
Show more

Hemispherx BioPharma Office Locations

Hemispherx BioPharma has an office in Philadelphia
Philadelphia, US (HQ)
One Penn Center, 1617 John F Kennedy Blvd #1190
Philadelphia, US
1617, One Penn Center, John F Kennedy Blvd Suite 555
Show all (2)

Hemispherx BioPharma Financials and Metrics

Hemispherx BioPharma Revenue

Hemispherx BioPharma's revenue was reported to be $367 k in FY, 2018
USD

Net income (Q1, 2019)

(3.4m)

EBIT (Q1, 2019)

(2.9m)

Market capitalization (22-May-2019)

11.2m

Closing stock price (22-May-2019)

0.1

Cash (31-Mar-2019)

2.4m
Hemispherx BioPharma's current market capitalization is $11.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

150.0k197.0k133.0k92.0k437.0k367.0k

Revenue growth, %

31%(32%)(31%)

General and administrative expense

7.7m9.1m7.1m7.7m6.6m6.2m

R&D expense

8.4m9.0m8.0m5.1m4.1m4.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

36.0k76.0k36.0k45.0k36.0k47.0k23.0k39.0k15.0k22.0k84.0k213.0k90.0k56.0k33.0k38.0k

General and administrative expense

2.1m2.5m2.5m2.2m1.9m2.0m1.7m2.4m1.6m1.6m1.7m1.6m1.6m1.6m1.7m1.3m1.8m

R&D expense

2.2m2.3m2.3m1.9m2.7m2.4m2.0m1.0m900.0k1.3m1.4m1.1m787.0k855.0k1.3m1.6m928.0k

Operating expense total

4.5m5.2m5.1m4.4m4.6m4.9m4.0m3.7m2.8m3.2m3.3m2.9m2.7m2.6m3.3m3.1m2.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

803.0k2.2m2.1m2.4m1.4m299.0k

Accounts Receivable

24.0k235.0k

Inventories

399.0k335.0k

Current Assets

18.6m16.5m10.6m6.9m3.5m3.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

1.6m4.1m2.6m1.3m2.9m1.8m1.2m1.0m1.5m4.5m776.0k1.2m503.0k4.0m3.6m4.1m2.4m

Accounts Receivable

41.0k98.0k42.0k29.0k35.0k28.0k101.0k

Inventories

626.0k

Current Assets

29.6m21.9m20.5m17.7m17.9m17.1m14.0m9.5m10.7m9.3m5.2m4.7m3.7m5.7m5.3m4.9m5.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(16.2m)(17.4m)(15.2m)(7.5m)(8.3m)(9.8m)

Depreciation and Amortization

671.0k665.0k941.0k1.1m948.0k856.0k

Inventories

(1.3m)

Accounts Payable

(617.0k)869.0k(196.0k)(326.0k)566.0k166.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(13.0m)(3.8m)(8.8m)(13.0m)(3.4m)(8.3m)(12.1m)(2.2m)(3.5m)(6.3m)(2.8m)(5.0m)(6.3m)(2.7m)(5.1m)(8.2m)(3.4m)

Depreciation and Amortization

504.0k167.0k332.0k500.0k180.0k458.0k663.0k300.0k576.0k854.0k261.0k504.0k739.0k216.0k444.0k658.0k194.0k

Inventories

453.0k(480.0k)(1.0m)(1.3m)

Accounts Payable

(197.0k)(16.0k)238.0k1.2m236.0k189.0k97.0k182.0k178.0k(202.0k)103.0k85.0k174.0k245.0k126.0k277.0k87.0k
USDY, 2019

Financial Leverage

4.1 x
Show all financial metrics

Hemispherx BioPharma News and Updates

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

Orlando, FL - (NewMediaWire) - May 13, 2019 - Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening o…

Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer

OCALA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the company’s new Chief Accounting Off…

Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that the subscription period for the rights …

Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record

To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timing

Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

OCALA, Fla., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today provided an update to stockholders regarding the Compa…

Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

The Phase II Study Will Combine Hemispherx’s Ampligen with Keytruda The Phase II Study Will Combine Hemispherx’s Ampligen with Keytruda
Show more

Hemispherx BioPharma Frequently Asked Questions

  • When was Hemispherx BioPharma founded?

    Hemispherx BioPharma was founded in 1990.

  • Who are Hemispherx BioPharma key executives?

    Hemispherx BioPharma's key executives are David R. Strayer, Peter W. Rodino and Wayne Springate.

  • How many employees does Hemispherx BioPharma have?

    Hemispherx BioPharma has 25 employees.

  • What is Hemispherx BioPharma revenue?

    Latest Hemispherx BioPharma annual revenue is $367 k.

  • What is Hemispherx BioPharma revenue per employee?

    Latest Hemispherx BioPharma revenue per employee is $14.7 k.

  • Who are Hemispherx BioPharma competitors?

    Competitors of Hemispherx BioPharma include Otonomy, Biogen and Shire.

  • Where is Hemispherx BioPharma headquarters?

    Hemispherx BioPharma headquarters is located at One Penn Center, 1617 John F Kennedy Blvd #1190, Philadelphia.

  • Where are Hemispherx BioPharma offices?

    Hemispherx BioPharma has an office in Philadelphia.

  • How many offices does Hemispherx BioPharma have?

    Hemispherx BioPharma has 2 offices.